← FDA DRUG APPROVALS

FDA ANDA · ANDA040359

ESTROPIPATE

Sponsor: PHARMOBEDIENT

APPLICATION
ANDA040359
TYPE
ANDA
ORIGINAL APPROVAL
1999-08-26
LATEST ACTION
2024-02-15
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

ESTROPIPATEDiscontinued
ESTROPIPATE 3MG · TABLET · ORAL
ESTROPIPATEDiscontinued
ESTROPIPATE 0.75MG · TABLET · ORAL
ESTROPIPATEDiscontinued
ESTROPIPATE 1.5MG · TABLET · ORAL

Approval history

2024-02-15Labeling · Supplement 6 · standardAP
2009-10-16Labeling · Supplement 4AP
2002-04-19Manufacturing (CMC) · Supplement 1AP
1999-08-26OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →